FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385880422> ?p ?o ?g. }

• W4385880422 endingPage "155025" @default.
• W4385880422 startingPage "155025" @default.
• W4385880422 abstract "Huashi Baidu granule (HSBD) and Paxlovid (Nirmatrelvir-Ritonavir) are antiviral Chinese patent medicine and western medicine specially developed for treating coronavirus disease 2019 (COVID-19). Their efficacy and safety in treating COVID-19 are still under investigated. To assess and compare the efficacy and safety of HSBD, Paxlovid, and the combination in treating high-risk patients infected with SARS-CoV-2 Omicron. The study was a prospective single-center, open-label, randomized, controlled clinical trial conducted from April 18 to June 5, 2022. (ClinicalTrial.gov registration number: ChiCTR2200059390) 312 severe patients aged 18 years and older infected with SARS-CoV-2 Omicron from Shuguang Hospital in Shanghai were randomly allocated to HSBD monotherapy (orally 137 g twice daily for 7 days, n=105), Paxlovid monotherapy (orally 300 mg of Nirmatrelvir plus 100 mg of Ritonavir every 12 hours for 5 days, n=103), or combination therapy (n=104). The primary outcome was SARS-CoV-2 nucleic acid negative conversion within 7-day treatment. The secondary outcome included hospital discharging conditions, severe conversion of symptom, and adverse events. Of 312 participants, 85 (82%) of 104 in combination therapy, 71 (68%) of 105 in HSBD monotherapy, and 73 (71%) of 103 in Paxlovid monotherapy had a primary outcome event. The hazard ratios of primary outcome were 1.37 (95% CI 1.03-1.84, p=0.012) for combination versus HSBD, 1.28 (0.98-1.69, p=0.043) for combination versus Paxlovid, and 0.88 (0.66-1.18, p=0.33) for HSBD versus Paxlovid. There was no statistical difference of efficacy between HSBD and Paxlovid, while combination therapy exhibited more effective than either alone. For secondary outcomes, the hospital discharging rates within 7 days exhibited the significant increase in combination therapy than in HSBD or Paxlovid monotherapy (71% (74/104) vs 55% (58/105) vs 52% (54/103), p<0.05). The risk of severe conversion of symptom showed no statistical significance among three interventions (1% (1/104) vs 3% (3/105) vs 3% (3/103), p>0.05). No severe adverse events occurred among combination therapy and monotherapies in the trial. For patients with severe COVID-19, HSBD exhibits similar efficacy to Paxlovid, while combination therapy is more likely to increase the curative efficacy of Omicron variant than monotherapies, with few serious adverse events." @default.
• W4385880422 created "2023-08-17" @default.
• W4385880422 creator A5003128018 @default.
• W4385880422 creator A5007564557 @default.
• W4385880422 creator A5012558857 @default.
• W4385880422 creator A5021603409 @default.
• W4385880422 creator A5025832492 @default.
• W4385880422 creator A5028674351 @default.
• W4385880422 creator A5029797583 @default.
• W4385880422 creator A5037050291 @default.
• W4385880422 creator A5038851564 @default.
• W4385880422 creator A5051223797 @default.
• W4385880422 creator A5059071043 @default.
• W4385880422 creator A5063001658 @default.
• W4385880422 creator A5072927762 @default.
• W4385880422 creator A5072953616 @default.
• W4385880422 creator A5085066243 @default.
• W4385880422 creator A5092650151 @default.
• W4385880422 creator A5092650152 @default.
• W4385880422 creator A5092650153 @default.
• W4385880422 date "2023-11-01" @default.
• W4385880422 modified "2023-10-14" @default.
• W4385880422 title "Efficacy and safety of Huashi Baidu granule plus Nirmatrelvir-Ritonavir combination therapy in patients with high-risk factors infected with Omicron (B.1.1.529): a multi-arm single-center, open-Label, randomized controlled trial" @default.
• W4385880422 cites W2027484375 @default.
• W4385880422 cites W2111149452 @default.
• W4385880422 cites W2163761019 @default.
• W4385880422 cites W2941905571 @default.
• W4385880422 cites W3007940623 @default.
• W4385880422 cites W3016403534 @default.
• W4385880422 cites W3033888056 @default.
• W4385880422 cites W3041007532 @default.
• W4385880422 cites W3041403959 @default.
• W4385880422 cites W3082355253 @default.
• W4385880422 cites W3082891494 @default.
• W4385880422 cites W3092282736 @default.
• W4385880422 cites W3097475974 @default.
• W4385880422 cites W3133997200 @default.
• W4385880422 cites W3189646261 @default.
• W4385880422 cites W3198329102 @default.
• W4385880422 cites W3214271933 @default.
• W4385880422 cites W4200113990 @default.
• W4385880422 cites W4210642183 @default.
• W4385880422 cites W4226023710 @default.
• W4385880422 cites W4226236384 @default.
• W4385880422 cites W4229038932 @default.
• W4385880422 cites W4280623099 @default.
• W4385880422 doi "https://doi.org/10.1016/j.phymed.2023.155025" @default.
• W4385880422 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37639813" @default.
• W4385880422 hasPublicationYear "2023" @default.
• W4385880422 type Work @default.
• W4385880422 citedByCount "0" @default.
• W4385880422 crossrefType "journal-article" @default.
• W4385880422 hasAuthorship W4385880422A5003128018 @default.
• W4385880422 hasAuthorship W4385880422A5007564557 @default.
• W4385880422 hasAuthorship W4385880422A5012558857 @default.
• W4385880422 hasAuthorship W4385880422A5021603409 @default.
• W4385880422 hasAuthorship W4385880422A5025832492 @default.
• W4385880422 hasAuthorship W4385880422A5028674351 @default.
• W4385880422 hasAuthorship W4385880422A5029797583 @default.
• W4385880422 hasAuthorship W4385880422A5037050291 @default.
• W4385880422 hasAuthorship W4385880422A5038851564 @default.
• W4385880422 hasAuthorship W4385880422A5051223797 @default.
• W4385880422 hasAuthorship W4385880422A5059071043 @default.
• W4385880422 hasAuthorship W4385880422A5063001658 @default.
• W4385880422 hasAuthorship W4385880422A5072927762 @default.
• W4385880422 hasAuthorship W4385880422A5072953616 @default.
• W4385880422 hasAuthorship W4385880422A5085066243 @default.
• W4385880422 hasAuthorship W4385880422A5092650151 @default.
• W4385880422 hasAuthorship W4385880422A5092650152 @default.
• W4385880422 hasAuthorship W4385880422A5092650153 @default.
• W4385880422 hasConcept C126322002 @default.
• W4385880422 hasConcept C142462285 @default.
• W4385880422 hasConcept C142724271 @default.
• W4385880422 hasConcept C159047783 @default.
• W4385880422 hasConcept C188947578 @default.
• W4385880422 hasConcept C197934379 @default.
• W4385880422 hasConcept C204787440 @default.
• W4385880422 hasConcept C207103383 @default.
• W4385880422 hasConcept C2522874641 @default.
• W4385880422 hasConcept C2776999253 @default.
• W4385880422 hasConcept C2779298103 @default.
• W4385880422 hasConcept C2780073493 @default.
• W4385880422 hasConcept C2993143319 @default.
• W4385880422 hasConcept C44249647 @default.
• W4385880422 hasConcept C71924100 @default.
• W4385880422 hasConceptScore W4385880422C126322002 @default.
• W4385880422 hasConceptScore W4385880422C142462285 @default.
• W4385880422 hasConceptScore W4385880422C142724271 @default.
• W4385880422 hasConceptScore W4385880422C159047783 @default.
• W4385880422 hasConceptScore W4385880422C188947578 @default.
• W4385880422 hasConceptScore W4385880422C197934379 @default.
• W4385880422 hasConceptScore W4385880422C204787440 @default.
• W4385880422 hasConceptScore W4385880422C207103383 @default.
• W4385880422 hasConceptScore W4385880422C2522874641 @default.
• W4385880422 hasConceptScore W4385880422C2776999253 @default.
• W4385880422 hasConceptScore W4385880422C2779298103 @default.
• W4385880422 hasConceptScore W4385880422C2780073493 @default.
• W4385880422 hasConceptScore W4385880422C2993143319 @default.

• next